In a research report published this morning, Cantor analyst Mara Goldstein reiterated a Buy rating on Array Biopharma (NASDAQ:ARRY) with a $9.00 price target, as …
William Blair analyst John Sonnier reiterated an Outperform rating on Array Biopharma (NASDAQ:ARRY), following the news that the company has regained worldwide rights to binimetinib …
In a research report released Thursday, Cantor analyst Mara Goldstein maintained a Buy rating on Array BioPharma (NASDAQ:ARRY) with a $9 price target, as the …
